Cargando…
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
In the past 10 years, immune checkpoint inhibitors (ICIs) have become an additional pillar of cancer therapy by activating the immune system to treat a number of different malignancies. Many patients receiving ICIs develop immune-related adverse events (irAEs) that mimic some features of classical a...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204615/ https://www.ncbi.nlm.nih.gov/pubmed/32303614 http://dx.doi.org/10.1136/jitc-2019-000356 |